Deciphera Pharmaceuticals
OverviewSuggest Edit
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company. It develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies.
| Type | Public | |
| Founded | 2003 | |
| HQ | Waltham, MA, US | Map |
| Website | deciphera.com | |
| Employee Ratings | More |
Recent NewsAll News
- Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® (Ripretinib) in a Multi-Regional Agreement
- Thinking about buying stock in Canopy Growth, Deciphera Pharmaceuticals, Genworth Financial, JD.Com, or Tilray?
- Deciphera Pharmaceuticals stock more than doubles on heavy volume after positive trial data
- VC-backed Deciphera Pharmaceuticals debuts IPO
Key People/Management at Deciphera Pharmaceuticals
Michael D. Taylor
Director
Steven L. Hoerter
President & CEO, Director
Daniel L. Flynn
Executive Vice President, Chief Scientific Officer and Founder
Jeff Held
Senior Vice President, General Counsel
Caroline Chevalier
Vice President, Human Resources
Tucker Kelly
Executive Vice President, Chief Financial Officer and Treasurer
Deciphera Pharmaceuticals Office Locations
Deciphera Pharmaceuticals has offices in Waltham and Lawrence
Waltham, MA, US (HQ)
10 CityPoint, 500 Totten Pond Rd 6th Floor
Lawrence, KS, US
643 Massachusetts St #200
Waltham, MA, US
200 Smith St
Deciphera Pharmaceuticals Financials and Metrics
Deciphera Pharmaceuticals Revenue
| USD | |
|---|---|
Net income (Q3, 2017) | (12.0m) |
EBIT (Q3, 2017) | (12.2m) |
Market capitalization (7-May-2021) | 2.0b |
Closing stock price (7-May-2021) | 34.3 |
Cash (30-Sept-2017) | 82.1m |
Deciphera Pharmaceuticals's current market capitalization is $2 b.
Annual
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash | 25.8m | 57.5m |
Prepaid Expenses | 606.0k | 791.0k |
Current Assets | 26.4m | 58.3m |
PP&E | 387.0k | 514.0k |
Quarterly
| USD | Q2, 2017 | Q3, 2017 |
|---|---|---|
Cash | 94.0m | 82.1m |
Prepaid Expenses | 580.0k | 596.0k |
Current Assets | 94.6m | 82.7m |
PP&E | 520.0k | 731.0k |
Annual
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Net Income | (19.8m) | (25.9m) |
Depreciation and Amortization | 73.0k | 90.0k |
Accounts Payable | 1.2m | (187.0k) |
Cash From Operating Activities | (13.3m) | (23.1m) |
Quarterly
| USD | Q2, 2016 | Q3, 2016 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|
Net Income | (11.3m) | (17.4m) | (18.3m) | (30.4m) |
Depreciation and Amortization | 38.0k | 60.0k | 62.0k | 101.0k |
Accounts Payable | 846.0k | (349.0k) | 446.0k | 1.4m |
Cash From Operating Activities | (9.8m) | (16.2m) | (15.1m) | (23.9m) |
| USD | FY, 2015 |
|---|---|
Financial Leverage | -0.2 x |
Deciphera Pharmaceuticals Operating Metrics
Show all operating metricsDeciphera Pharmaceuticals Cybersecurity Score
Deciphera Pharmaceuticals Environment, Social & Governance (ESG) Ratings
Deciphera Pharmaceuticals Online and Social Media Presence
Deciphera Pharmaceuticals's Trends
Deciphera Pharmaceuticals News and Updates
November 06, 2020
Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® (Ripretinib) in a Multi-Regional Agreement
PETACH TIKVA, Israel and WALTHAM, Mass., Nov. 6, 2020 /PRNewswire/ -- Medison Pharma, a leading international commercial partner for highly innovative therapies, today announced an exclusive distribution agreement with Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) to commercialize...
August 13, 2019
Thinking about buying stock in Canopy Growth, Deciphera Pharmaceuticals, Genworth Financial, JD.Com, or Tilray?
NEW YORK, Aug. 13, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, DCPH, GNW, JD, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
August 13, 2019
Deciphera Pharmaceuticals stock more than doubles on heavy volume after positive trial data
Shares of Deciphera Pharmaceuticals Inc. more than doubled toward a 14-month high in active premarket trading Tuesday, after the biopharmaceutical company said a phase 3 trial of its treatment of gastrointestinal stromal tumors (GIST) achieved its primary endpoint, paving the way for the company to…
September 28, 2017
VC-backed Deciphera Pharmaceuticals debuts IPO
Waltham, Massachusetts-based Deciphera Pharmaceuticals, an biotechnology company focused on key mechanisms of tumor drug resistance, has raised $127.5 million for its IPO after pricing its 7.5 million shares at $17 per share. The stock began trading Thursday September 28, 2017 on the NASDAQ under th…
Deciphera Pharmaceuticals Blogs
July 13, 2020
Rodrigo Ruiz Soto
Rodrigo Ruiz Soto, MD/MSc has served as Vice President of Clinical Development and Translational Medicine since May 2017. Dr. Ruiz Soto is an experienced Clinical Development Hematologist-Oncologist with more than 15 years of experience in Clinical Research. Prior to Deciphera, Dr. Ruiz Soto was Sen…
November 27, 2019
Matthew L. Sherman, M.D.
Matthew L. Sherman, M.D. is Executive Vice President and Chief Medical Officer of Deciphera Pharmaceuticals. Dr. Sherman brings over 25 years of experience as a physician-scientist in clinical drug development in oncology and hematology at leading biotechnology and pharmaceutical companies. From 200…
August 27, 2019
Sr. Director, Market Access (Field Leader)
Job #: 03-252 Job Title: Sr. Director, Market Access (Field Leader) Reports to: Vice President, Market Access Location: Waltham, MA Company Summary: Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients. We have used our proprieta…
August 26, 2019
SEC Reporting Manager
Job #: 03-251 Job Title: SEC Reporting Manager Location: Waltham, MA Company Overview: Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients. We have used our proprietary drug discovery platform to develop a diverse pipeline of drug…
August 26, 2019
Senior Financial Analyst
Job #: 03-250 Job Title: Senior Financial Analyst Location: Waltham, MA Company Overview: Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients. We have used our proprietary drug discovery platform to develop a diverse pipeline…
August 20, 2019
Sr. Commercial Contracts Counsel
Job #: 03-248 Job Title: Sr. Commercial Contracts Counsel Location: Waltham, MA Company Summary: Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients. We have used our proprietary drug discovery platform to develop a diverse pipe…
Deciphera Pharmaceuticals Frequently Asked Questions
When was Deciphera Pharmaceuticals founded?
Deciphera Pharmaceuticals was founded in 2003.
Who are Deciphera Pharmaceuticals key executives?
Deciphera Pharmaceuticals's key executives are Michael D. Taylor, Steven L. Hoerter and Daniel L. Flynn.
How many employees does Deciphera Pharmaceuticals have?
Deciphera Pharmaceuticals has 43 employees.
Who are Deciphera Pharmaceuticals competitors?
Competitors of Deciphera Pharmaceuticals include DemeRx, Closed Loop Medicine and Juvenescence.
Where is Deciphera Pharmaceuticals headquarters?
Deciphera Pharmaceuticals headquarters is located at 10 CityPoint, 500 Totten Pond Rd 6th Floor, Waltham.
Where are Deciphera Pharmaceuticals offices?
Deciphera Pharmaceuticals has offices in Waltham and Lawrence.
How many offices does Deciphera Pharmaceuticals have?
Deciphera Pharmaceuticals has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies